These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18251583)

  • 1. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors.
    Takeda Y; Tsuta K; Shibuki Y; Hoshino T; Tochigi N; Maeshima AM; Asamura H; Sasajima Y; Ito T; Matsuno Y
    Arch Pathol Lab Med; 2008 Feb; 132(2):239-43. PubMed ID: 18251583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors.
    Chia SY; Thike AA; Cheok PY; Tan PH
    Breast; 2010 Oct; 19(5):355-9. PubMed ID: 20347310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer.
    Fritzsche FR; Thomas A; Winzer KJ; Beyer B; Dankof A; Bellach J; Dahl E; Dietel M; Kristiansen G
    Histol Histopathol; 2007 Nov; 22(11):1221-30. PubMed ID: 17647195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
    Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
    Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry.
    Huo L; Gong Y; Guo M; Gilcrease MZ; Wu Y; Zhang H; Zhang J; Resetkova E; Hunt KK; Deavers MT
    Histopathology; 2015 Aug; 67(2):245-54. PubMed ID: 25564996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity.
    Bhargava R; Beriwal S; Dabbs DJ
    Am J Clin Pathol; 2007 Jan; 127(1):103-13. PubMed ID: 17145637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma.
    Han JH; Kang Y; Shin HC; Kim HS; Kang YM; Kim YB; Oh SY
    Arch Pathol Lab Med; 2003 Oct; 127(10):1330-4. PubMed ID: 14521461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers of metastatic carcinoma of breast origin.
    Gown AM; Fulton RS; Kandalaft PL
    Histopathology; 2016 Jan; 68(1):86-95. PubMed ID: 26768031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
    Hafez NH; Shaaban HM
    Turk Patoloji Derg; 2018; 34(2):143-149. PubMed ID: 29235613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer.
    Huo L; Zhang J; Gilcrease MZ; Gong Y; Wu Y; Zhang H; Resetkova E; Hunt KK; Deavers MT
    Histopathology; 2013 Jan; 62(2):267-74. PubMed ID: 22963676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin.
    Lewis GH; Subhawong AP; Nassar H; Vang R; Illei PB; Park BH; Argani P
    Am J Clin Pathol; 2011 Apr; 135(4):587-91. PubMed ID: 21411781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
    Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens.
    Yan Z; Gidley J; Horton D; Roberson J; Eltoum IE; Chhieng DC
    Diagn Cytopathol; 2009 Jul; 37(7):475-8. PubMed ID: 19217055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
    Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin.
    Wick MR; Lillemoe TJ; Copland GT; Swanson PE; Manivel JC; Kiang DT
    Hum Pathol; 1989 Mar; 20(3):281-7. PubMed ID: 2542151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast.
    Lopez-Bonet E; Pérez-Martínez MC; Martin-Castillo B; Alonso-Ruano M; Tuca F; Oliveras-Ferraros C; Cufí S; Vazquez-Martin A; Beltràn M; Bernadó L; Menendez JA
    Breast Cancer Res Treat; 2011 Feb; 126(1):241-5. PubMed ID: 20978935
    [No Abstract]   [Full Text] [Related]  

  • 18. Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin.
    Kanner WA; Galgano MT; Stoler MH; Mills SE; Atkins KA
    Int J Gynecol Pathol; 2008 Oct; 27(4):491-5. PubMed ID: 18753974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
    Ciampa A; Fanger G; Khan A; Rock KL; Xu B
    Cancer; 2004 Dec; 102(6):368-72. PubMed ID: 15558786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens.
    Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z
    Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.